An earlier online version of the paper contained some typographical errors in the Table 3, Table 4. These Tables have now been corrected and the corrections do not change the results or conclusions of the study. The authors apologize for the errors.
Table 3.
Effects of omega-3 supplements on serum lipids by different genotypes at NOS3 (rs1799983).†
| Total omega-3 supplements |
Fish oil supplements |
Flaxseed oil supplements |
Control |
||||||
|---|---|---|---|---|---|---|---|---|---|
| AA/AC (n = 10) | CC (n = 90) | AA/AC (n = 3) | CC (n = 53) | AA/AC (n = 7) | CC (n = 37) | AA/AC (n = 11) | CC (n = 39) | ||
| HDL-C | Baseline | 1.13 (0.30) | 1.17 (0.31) | 1.38 (0.37) | 1.13 (0.30) | 1.03 (0.21) | 1.21 (0.32) | 1.17 (0.15) | 1.18 (0.20) |
| After intervention | 1.32 (0.29) | 1.21 (0.31) | 1.64 (0.33) | 1.21 (0.29) | 1.19 (0.13) | 1.22 (0.33) | 1.22 (0.19) | 1.26 (0.26) | |
| Change | 0.19 (0.12) | 0.06 (0.22) | 0.26 (0.14) | 0.08 (0.23) | 0.16 (0.11) | 0.03 (0.19) | 0.09 (0.10) | 0.07 (0.19) | |
| LDL-C | Baseline | 3.02 (0.69) | 2.94 (0.86) | 3.24 (1.02) | 2.95 (0.83) | 2.93 (0.58) | 2.94 (0.92) | 2.84 (0.54) | 3.14 (0.94) |
| After intervention | 2.87 (0.75) | 2.79 (0.78) | 2.14 (0.31) | 2.71 (0.82) | 3.19 (0.66) | 2.91 (0.71) | 2.92 (0.63) | 3.08 (1.00) | |
| Change | −0.15 (1.08) | −0.17 (0.77) | −1.10 (0.96) | −0.27 (0.86) | 0.26 (0.9) | −0.02 (0.59) | 0.19 (0.93) | −0.11 (0.78) | |
| TC | Baseline | 4.72 (0.98) | 4.71 (0.95) | 5.38 (1.45) | 4.66 (0.94) | 4.44 (0.65) | 4.77 (0.97) | 4.66 (0.80) | 4.95 (1.10) |
| After intervention | 4.96 (1.13) | 4.71 (0.95) | 4.13 (0.41) | 4.60 (1.01) | 5.32 (1.17) | 4.86 (0.83) | 4.54 (0.75) | 5.23 (1.22) | |
| Change | 0.24 (1.39) | −0.02 (0.75) | −1.25 (1.04) | −0.11 (0.76) | 0.88 (0.97) | 0.13 (0.72) | 0.06 (1.12) | 0.32 (0.94) | |
| TC/HDL-C | Baseline | 4.30 (0.92) | 4.24 (1.13) | 3.93 (0.71) | 4.30 (1.11) | 4.46 (1.00) | 4.15 (1.18) | 4.02 (0.70) | 4.25 (1.00) |
| After intervention | 3.90 (1.12) | 4.07 (1.14) | 2.58 (0.48) | 3.95 (1.01) | 4.46 (0.75) | 4.26 (1.30) | 3.75 (0.65) | 4.37 (1.73) | |
| Change | −0.40 (1.03) | −0.21 (0.86) | −1.36 (0.32) | −0.42 (0.78) | 0.00 (0.96) | 0.09 (0.89) | −0.24 (0.83) | 0.13 (1.74) | |
| TG (log-transformed) | Baseline | 0.48 (0.46) | 0.42 (0.51) | 0.65 (0.41) | 0.42 (0.47) | 0.41 (0.49) | 0.43 (0.57) | 0.45 (0.46) | 0.53 (0.49) |
| After intervention | 0.40 (0.43) | 0.33 (0.54) | 0.19 (0.46) | 0.26 (0.51) | 0.49 (0.41) | 0.43 (0.58) | 0.47 (0.44) | 0.47 (0.50) | |
| Change | −0.08 (0.31) | −0.11 (0.39) | −0.46 (0.15) | −0.16 (0.37) | 0.08 (0.19) | −0.03 (0.42) | −0.02 (0.31) | −0.08 (0.37) | |
Values are presented as mean (SD). Total omega-3 supplement group is a combination of fish oil and flaxseed oil groups. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. No interaction between NOS3 genotypes and omega-3 supplements for the lipid traits was observed.
Table 4.
Effects of omega-3 supplements on serum lipids by different genotypes at PPARG (rs1801282).†
| Total omega-3 supplements |
Fish oil supplements |
Flaxseed oil supplements |
Control |
||||||
|---|---|---|---|---|---|---|---|---|---|
| GG/GC (n = 12) | CC (n = 88) | GG/GC (n = 8) | CC (n = 48) | GG/GC (n = 4) | CC (n = 40) | GG/GC (n = 5) | CC (n = 45) | ||
| HDL-C | Baseline | 1.20 (0.28) | 1.16 (0.31) | 1.16 (0.31) | 1.14 (0.31) | 1.26 (0.26) | 1.17 (0.31) | 1.22 (0.13) | 1.18 (0.19) |
| After intervention | 1.28 (0.25) | 1.22 (0.31) | 1.26 (0.25) | 1.23 (0.32) | 1.34 (0.31) | 1.20 (0.31) | 1.31 (0.12) | 1.25 (0.26) | |
| Change | 0.08 (0.27) | 0.07 (0.21) | 0.10 (0.29) | 0.09 (0.22) | 0.03 (0.22) | 0.05 (0.19) | 0.07 (0.13) | 0.08 (0.18) | |
| LDL-C | Baseline | 3.35 (0.77) | 2.90 (0.84) | 3.19 (0.86) | −0.26 (0.85) | 3.67 (0.51) | 0.05 (0.66) | 2.77 (0.58) | 3.11 (0.89) |
| After intervention | 2.76 (0.68) | 2.80 (0.79) | 2.53 (0.63) | 2.92 (0.83) | 3.36 (0.39) | 2.86 (0.87) | 3.47 (0.54) | 3.00 (0.96) | |
| Change⁎ | −0.54 (0.87) | −0.12 (0.78) | −0.65 (0.98) | 2.71 (0.84) | −0.23 (0.47) | 2.92 (0.71) | 0.80 (0.68) | −0.13 (0.78) | |
| TC | Baseline | 5.23 (1.18) | 4.64 (0.89) | 4.92 (1.18) | 4.66 (0.94) | 5.85 (1.05) | 4.60 (0.85) | 4.60 (0.81) | 4.92 (1.06) |
| After intervention | 4.91 (1.03) | 4.71 (0.96) | 4.66 (1.15) | 4.55 (0.98) | 5.49 (0.26) | 4.90 (0.91) | 5.27 (0.79) | 5.07 (1.20) | |
| Change | −0.43 (0.94) | 0.07 (0.81) | −0.43 (0.99) | −0.14 (0.79) | −0.42 (1.02) | 0.31 (0.78) | 0.61 (0.80) | 0.23 (0.99) | |
| TC/HDL-C | Baseline | 4.49 (0.99) | 4.21 (1.13) | 4.38 (1.12) | 4.26 (1.10) | 4.71 (0.77) | 4.15 (1.17) | 3.75 (0.28) | 4.24 (0.98) |
| After intervention | 3.97 (1.06) | 4.06 (1.14) | 3.86 (1.15) | 3.87 (1.03) | 4.25 (0.96) | 4.30 (1.24) | 4.04 (0.49) | 4.27 (1.66) | |
| Change | −0.55 (1.24) | −0.19 (0.83) | −0.63 (1.51) | −0.45 (0.65) | −0.35 (0.07) | 0.11 (0.92) | 0.29 (0.41) | 0.03 (1.67) | |
| TG (log-transformed) | Baseline | 0.56 (0.54) | 0.41 (0.49) | 0.42 (0.49) | 0.43 (0.46) | 0.85 (0.59) | 0.39 (0.54) | 0.49 (0.57) | 0.51 (0.47) |
| After intervention | 0.42 (0.43) | 0.32 (0.54) | 0.32 (0.47) | 0.24 (0.51) | 0.67 (0.12) | 0.42 (0.56) | 0.81 (0.36) | 0.44 (0.48) | |
| Change | −0.17 (0.41) | −0.10 (0.38) | −0.10 (0.37) | −0.19 (0.37) | −0.35 (0.55) | 0.02 (0.37) | 0.10 (0.20) | −0.09 (0.37) | |
Values are presented as mean (SD). Total omega-3 supplement group is a combination of fish oil and flaxseed oil groups. HDL-C, high cv LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
Significant interaction (p-interaction = 0.02) between the PPARG genotypes and the omega-3 supplements for the change in LDL-C was observed in the general linear model, after adjustment for age, sex, study centre, BMI and baseline value of corresponding outcome. PPARG G allele carriers had a higher increase in LDL-C level compared with CC carriers among control group (p = 0.022), while no difference was observed among omega-3 groups.